Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder

George I. Papakostas, Timothy Petersen, Katherine G. Sklarsky, Andrew A. Nierenberg, Jonathan E. Alpert, Maurizio Fava

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The goal of the present work is to assess for the relationship between the timing of clinical improvement and the resolution of depressive symptoms in Major Depressive Disorder (MDD). 182 MDD outpatients (40.5 ± 9.7 years; 53.8% female) who responded following an 8-week, 20 mg, open trial of fluoxetine were included in the analysis. The symptoms questionnaire (SQ) and Beck hopelessness scale (BHS) were also administered to 83 and 153 of these patients, respectively. Onset of clinical improvement was defined as a 30% decrease in 17-item Hamilton depression scale (HDRS-17) scores. Controlling for baseline symptom severity, we then assessed for the relationship between the timing of clinical improvement and depressive symptom at endpoint. Earlier clinical improvement in responders predicted lower HDRS-17, BHS, SQ-depression, SQ-anxiety, but not SQ-somatic symptom or SQ-anger/hostility scores at week 8. This was true regardless of whether improvement was defined as a continuous measure (30% decrease in symptom severity), as a dichotomous measure (clinical response occurring in the first two weeks of treatment). In conclusion, earlier clinical improvement with fluoxetine treatment is predictive of greater symptom resolution at endpoint. Further studies exploring the impact of various treatment modalities and placebo on the timing of clinical improvement and symptom resolution in MDD are warranted.

Original languageEnglish (US)
Pages (from-to)195-200
Number of pages6
JournalPsychiatry Research
Volume149
Issue number1-3
DOIs
StatePublished - Jan 15 2007
Externally publishedYes

Fingerprint

Major Depressive Disorder
Depression
Fluoxetine
Therapeutics
Hostility
Anger
Outpatients
Anxiety
Placebos
Surveys and Questionnaires

Keywords

  • Fluoxetine
  • Onset
  • Residual
  • Symptom

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. / Papakostas, George I.; Petersen, Timothy; Sklarsky, Katherine G.; Nierenberg, Andrew A.; Alpert, Jonathan E.; Fava, Maurizio.

In: Psychiatry Research, Vol. 149, No. 1-3, 15.01.2007, p. 195-200.

Research output: Contribution to journalArticle

Papakostas, George I. ; Petersen, Timothy ; Sklarsky, Katherine G. ; Nierenberg, Andrew A. ; Alpert, Jonathan E. ; Fava, Maurizio. / Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. In: Psychiatry Research. 2007 ; Vol. 149, No. 1-3. pp. 195-200.
@article{109ac0358ca84e05aec9f4253db5bfa1,
title = "Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder",
abstract = "The goal of the present work is to assess for the relationship between the timing of clinical improvement and the resolution of depressive symptoms in Major Depressive Disorder (MDD). 182 MDD outpatients (40.5 ± 9.7 years; 53.8{\%} female) who responded following an 8-week, 20 mg, open trial of fluoxetine were included in the analysis. The symptoms questionnaire (SQ) and Beck hopelessness scale (BHS) were also administered to 83 and 153 of these patients, respectively. Onset of clinical improvement was defined as a 30{\%} decrease in 17-item Hamilton depression scale (HDRS-17) scores. Controlling for baseline symptom severity, we then assessed for the relationship between the timing of clinical improvement and depressive symptom at endpoint. Earlier clinical improvement in responders predicted lower HDRS-17, BHS, SQ-depression, SQ-anxiety, but not SQ-somatic symptom or SQ-anger/hostility scores at week 8. This was true regardless of whether improvement was defined as a continuous measure (30{\%} decrease in symptom severity), as a dichotomous measure (clinical response occurring in the first two weeks of treatment). In conclusion, earlier clinical improvement with fluoxetine treatment is predictive of greater symptom resolution at endpoint. Further studies exploring the impact of various treatment modalities and placebo on the timing of clinical improvement and symptom resolution in MDD are warranted.",
keywords = "Fluoxetine, Onset, Residual, Symptom",
author = "Papakostas, {George I.} and Timothy Petersen and Sklarsky, {Katherine G.} and Nierenberg, {Andrew A.} and Alpert, {Jonathan E.} and Maurizio Fava",
year = "2007",
month = "1",
day = "15",
doi = "10.1016/j.psychres.2006.03.014",
language = "English (US)",
volume = "149",
pages = "195--200",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "1-3",

}

TY - JOUR

T1 - Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder

AU - Papakostas, George I.

AU - Petersen, Timothy

AU - Sklarsky, Katherine G.

AU - Nierenberg, Andrew A.

AU - Alpert, Jonathan E.

AU - Fava, Maurizio

PY - 2007/1/15

Y1 - 2007/1/15

N2 - The goal of the present work is to assess for the relationship between the timing of clinical improvement and the resolution of depressive symptoms in Major Depressive Disorder (MDD). 182 MDD outpatients (40.5 ± 9.7 years; 53.8% female) who responded following an 8-week, 20 mg, open trial of fluoxetine were included in the analysis. The symptoms questionnaire (SQ) and Beck hopelessness scale (BHS) were also administered to 83 and 153 of these patients, respectively. Onset of clinical improvement was defined as a 30% decrease in 17-item Hamilton depression scale (HDRS-17) scores. Controlling for baseline symptom severity, we then assessed for the relationship between the timing of clinical improvement and depressive symptom at endpoint. Earlier clinical improvement in responders predicted lower HDRS-17, BHS, SQ-depression, SQ-anxiety, but not SQ-somatic symptom or SQ-anger/hostility scores at week 8. This was true regardless of whether improvement was defined as a continuous measure (30% decrease in symptom severity), as a dichotomous measure (clinical response occurring in the first two weeks of treatment). In conclusion, earlier clinical improvement with fluoxetine treatment is predictive of greater symptom resolution at endpoint. Further studies exploring the impact of various treatment modalities and placebo on the timing of clinical improvement and symptom resolution in MDD are warranted.

AB - The goal of the present work is to assess for the relationship between the timing of clinical improvement and the resolution of depressive symptoms in Major Depressive Disorder (MDD). 182 MDD outpatients (40.5 ± 9.7 years; 53.8% female) who responded following an 8-week, 20 mg, open trial of fluoxetine were included in the analysis. The symptoms questionnaire (SQ) and Beck hopelessness scale (BHS) were also administered to 83 and 153 of these patients, respectively. Onset of clinical improvement was defined as a 30% decrease in 17-item Hamilton depression scale (HDRS-17) scores. Controlling for baseline symptom severity, we then assessed for the relationship between the timing of clinical improvement and depressive symptom at endpoint. Earlier clinical improvement in responders predicted lower HDRS-17, BHS, SQ-depression, SQ-anxiety, but not SQ-somatic symptom or SQ-anger/hostility scores at week 8. This was true regardless of whether improvement was defined as a continuous measure (30% decrease in symptom severity), as a dichotomous measure (clinical response occurring in the first two weeks of treatment). In conclusion, earlier clinical improvement with fluoxetine treatment is predictive of greater symptom resolution at endpoint. Further studies exploring the impact of various treatment modalities and placebo on the timing of clinical improvement and symptom resolution in MDD are warranted.

KW - Fluoxetine

KW - Onset

KW - Residual

KW - Symptom

UR - http://www.scopus.com/inward/record.url?scp=33846227445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846227445&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2006.03.014

DO - 10.1016/j.psychres.2006.03.014

M3 - Article

C2 - 17157390

AN - SCOPUS:33846227445

VL - 149

SP - 195

EP - 200

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 1-3

ER -